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Suppresses the IL-23/IL-17 Axis in Normalized
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James G. Krueger1 and Michelle A. Lowes1
Narrow-band UVB radiation (NB-UVB) therapy offers a well-established treatment modality for psoriasis.
However, despite the common use of this form of treatment, the mechanism of action of NB-UVB is not well
understood. We studied a group of 14 patients with moderate-to-severe psoriasis treated with carefully titrated
and monitored NB-UVB for 6 weeks. Lesional plaques were classified as normalized (n¼ 8) or nonresponsive
(n¼ 6) based on their histological improvement and normalization. We characterized lesional myeloid dendritic
cells (DCs) and T cells and their inflammatory mediators using immunohistochemistry and real-time PCR.
NB-UVB suppressed multiple parameters of the IL-23/IL-17 pathway in normalized plaques, but not in
nonresponsive plaques. NB-UVB decreased the numbers of CD11cþ DCs, specifically CD1cCD11cþ
‘‘inflammatory’’ DCs, and their products, IL-20, inducible nitric oxide synthase, IL-12/23p40, and IL-23p19.
Furthermore, effective NB-UVB suppressed IL-17 and IL-22 mRNAs, which strongly correlated with lesion
resolution. Therefore, in addition to its known role in suppressing IFN-g production, NB-UVB radiation therapy
can also target the IL-17 pathway to resolve psoriatic inflammation.
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INTRODUCTION
Psoriasis, a chronic, debilitating skin disease affecting millions
of Americans, is considered one of the most prevalent
immune-mediated inflammatory diseases (Lebwohl, 2003). It
has now become clear that infiltrating immune cells have very
important roles in disease pathogenesis. T cells and dendritic
cells (DCs) are significantly increased in lesional skin (LS)
compared with uninvolved, ‘‘non-lesional’’ skin (NL) (Cha-
mian et al., 2005; Lowes et al., 2005a). Along with the resident
dermal myeloid DCs present in normal skin, an additional
population of ‘‘inflammatory’’ DCs is detected in lesional
psoriatic skin (Lowes et al., 2005a; Zaba et al., 2009a). DCs
have an integral role in shaping the CD4þ T-cell response,
and the increased frequencies of IFN-g and IL-17/IL-22-
producing T cells observed in psoriatic lesional skin may be
due to the production of IL-12 and IL-23 by inflammatory DCs,
respectively (Zaba et al., 2007b; Guttman-Yassky et al., 2008;
Lowes et al., 2008; Pene et al., 2008). Whereas IFN-g and IL-
17 induce chemokine expression and cellular recruitment to
the skin, IL-22 leads to aberrant keratinocyte proliferation and
epidermal hyperplasia (Boniface et al., 2005; Sa et al., 2007;
Nograles et al., 2008). Thus, the development of psoriatic
lesions is likely due to the coordinated efforts of several
inflammatory cytokine pathways and treatments targeting
multiple facets of pathogenesis, and they are of great value.
UV radiation has been an effective treatment for psoriasis,
as well as other skin diseases, for 85 years, since it was first
used as a daily broad-band source (290–320 nm) combined
with topical tar, known as the ‘‘Goeckerman’’ regimen
(Goeckerman, 1925). Over the past 30 years, the introduction
of fluorescent bulbs with a limited spectrum of 311–312 nm
(narrow-band (NB)-UVB) has marked an advance in photo-
therapy, as this represents the wavelength with the optimal
‘‘phototherapy index.’’ When compared with conventional
broad-band UVB therapy, treatment with NB-UVB has been
found to have greater bioactivity (Walters et al., 1999).
However, we still do not fully understand the mechanism of
action of this remarkably effective therapy.
At the cellular level, NB-UVB therapy has many immu-
nosuppressive effects. It leads to a reduction of T cells
(Carrascosa et al., 2007; Erkin et al., 2007) by inducing
apoptosis (Krueger et al., 1995; Ozawa et al., 1999).
Keratinocyte apoptosis also occurs as a result of in vitro
NB-UVB (Aufiero et al., 2006), but it is probably not
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contributing to disease resolution in vivo as it is not detected
after treatment (Krueger et al., 1995). In addition, some
studies have found a decrease in the numbers of Langerhans
cells after therapy (Murphy et al., 1993; Tjioe et al., 2003),
although others have not found a significant decrease
(Carrascosa et al., 2007; Erkin et al., 2007). Nevertheless, it
is clear that NB-UVB impairs in vitro antigen presentation by
both murine DCs and human Langerhans cells, rendering
them tolerogenic rather than stimulatory (Noonan et al.,
1988; Baadsgaard et al., 1990; Simon et al., 1991; Murphy
et al., 1993; Goettsch et al., 1998). Thus, NB-UVB can
suppress a broad range of immune cells.
More recently, there have been efforts to understand
the effect of NB-UVB on inflammatory cytokine production.
NB-UVB specifically targets IFN-g-producing Th1 cells as
well as upstream cytokines, IL-12 and IL-23 (Piskin et al.,
2003; Walters et al., 2003; Piskin et al., 2004b). NB-UVB also
has suppressive effects on additional inflammatory mediators,
including IL-18, IL-8, IL-1b, and IL-6 (Walters et al., 2003;
Sigmundsdottir et al., 2005). However, although it is clear
that NB-UVB can suppress inflammatory cytokines, it is still
unknown whether NB-UVB can similarly target pathogenic
IL-17 production.
In this study, we sought to determine whether NB-UVB
influences the IL-17/IL-23 axis, which is considered a critical
pathogenic pathway in psoriasis (Blauvelt, 2008; Di Cesare
et al., 2009; Nestle et al., 2009). Psoriatic skin tissue was
analyzed in index plaques showing histological improvement
after NB-UVB therapy (normalized) and those that did not
respond (nonresponsive) by real-time PCR and immunohisto-
chemistry. We found that NB-UVB suppressed multiple para-
meters of the IL-23/IL-17 pathway in normalized plaques, but not
in nonresponsive plaques. Therefore, in addition to its known
role in reducing IFN-g production, NB-UVB therapy can also
resolve psoriatic inflammation by targeting the IL-23/IL-17 axis.
RESULTS
Classification of response
In this study, 14 adult patients with moderate-to-severe
psoriasis received a 6-week treatment regimen of regular,
monitored NB-UVB radiation therapy. Psoriasis area and
severity index (PASI) was decreased by over 50% (PASI 50) in
the vast majority of patients (93%), whereas 28% of patients
achieved over 75% improvement (PASI 75) by week 6 of
treatment (Supplementary Table S1 online). Response of an
index plaque to NB-UVB was further evaluated histologically
by measuring epidermal thickness and keratinocyte differ-
entiation by keratin 16 (K16) staining. Histological normal-
ization in an index plaque does not always correlate
with global clinical improvement as assessed by PASI.
Plaques with epidermal thinning and normalization of K16
staining and mRNA expression by week 6 after treatment
were classified as normalized (Figure 1a, c, and d), whereas
nonresponsive plaques retained a thickened epidermis
and strong K16 staining and mRNA (Figure 1b–d). Of the
14 plaques, 8 were histologically classified as normalized,
whereas 6 were considered nonresponsive. Subsequent
experiments presented in this study compare the outcome
of NB-UVB therapy in both normalized and nonresponsive
plaques.
We also used multivariate m-scores (Wittkowski et al.,
2004) to generate a ‘‘response score’’ for each plaque, taking
into account both percentage change in epidermal thickness
and K16 mRNA. Plaques were ranked according to their
response scores; the lower the response score, the better the
improvement of the plaque. The six plaques classified as
nonresponsive had the highest response scores, whereas
the remaining normalized plaques were ranked with lower
response scores (Supplementary Table S1 online). This
analysis provided a nonbiased, quantitative method to
correlate response with the percentage changes in gene
expression or cell counts over the treatment period.
Inflammatory DCs were decreased in normalized plaques
To begin to dissect the immune mechanism of disease control
by NB-UVB therapy, immunohistochemistry for DC markers
was performed on skin sections before and after treatment.
‘‘Resident’’ myeloid DCs in normal dermis are identified by
CD11cþ and CD1c (Zaba et al., 2009b). CD1cþ cells were
not present in the epidermis. Dermal CD1cþ cells did
not change in number during treatment with etanercept
(Zaba et al., 2007a), and similarly did not change during the
course of NB-UVB in normalized plaques (Figure 2a and c).
LS skin of nonresponsive plaques had a slight increase in
CD1cþ cells over NL skin, although this result was not
statistically significant.
In psoriasis lesions, we have previously found a dramatic
increase in a second population of myeloid ‘‘inflammatory’’
DCs (Lowes et al., 2005a; Zaba et al., 2009a) that express
CD11c, but not CD1c. Treatment of psoriasis with efalizu-
mab, alefacept, cyclosporine, or etanercept decreased these
inflammatory myeloid DCs (Chamian et al., 2005; Lowes
et al., 2005b; Zaba et al., 2007a; Haider et al., 2008). The
effect of NB-UVB on inflammatory DCs was assessed using
immunohistochemistry. Although fewer dermal CD11cþ
DCs were observed in NL skin compared with LS skin
(Figure 2b and d), by week 6 of NB-UVB, dermal CD11cþ
DCs were significantly reduced in normalized plaques, but
not in nonresponsive plaques. Similar results were observed
in the epidermis (Supplementary Figure S1a online).
Currently, there is no positive marker to identify the infla-
mmatory DCs. However, an approximation of the number of
CD11cþCD1c inflammatory DCs can be calculated by
subtracting the number of CD1cþ cells from CD11cþ cells.
Normalized plaques had decreased dermal CD11cþCD1c
inflammatory DCs, whereas nonresponsive plaques retained
a population of these cells (Figure 2e). To assess the
relationship between response and the downregulation
of these cell subsets, we used multivariate m-scores as
described above. There was a strong correlation between
epidermal CD11cþ cells and response score (r¼0.863,
P¼0.002; Supplementary Figure S1b online). Similarly,
dermal CD11cþ DCs correlated significantly with response
(r¼0.675, P¼0.015), whereas dermal CD1cþ cells did not
(r¼0.255, P¼ 0.362; Supplementary Figure S2 online).
Moreover, inflammatory DCs also had a significant
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correlation with response score (r¼0.664, P¼ 0.017; Sup-
plementary Figure S2 online). To further characterize
these DCs, two-color immunofluorescence was performed
using antibodies against CD11c and CD1c. The majority
of cells in NL skin costained for these two markers
(Supplementary Figure S3 online), whereas in LS skin, there
was a higher proportion of cells staining for CD11c, but not
CD1c (Figure 2f). After 6 weeks of NB-UVB, most cells
were CD11cþCD1cþ in normalized plaques, suggesting a
decrease in inflammatory DCs with effective treatment.
Nonresponsive plaques maintained a population of CD11cþ
CD1c DCs after treatment (data not shown). These data
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Figure 1. Classification of normalized and nonresponsive plaques. (a, b) Histological response was measured at baseline in non-lesional (NL) and lesional
(LS) skin and skin at 6 weeks after treatment (week 6). Representative histology and immunohistochemistry showing hematoxylin and eosin (H&E) and K16
expression in (a) normalized plaques and (b) nonresponsive plaques. Scale bar¼100 mm. (c) Epidermal thickness of normalized (black bars, n¼ 7)
and nonresponsive plaques (white bars, n¼6) before and after NB-UVB therapy. Error bars represent the mean±SEM. NL and week 6 values are compared
with LS. ***Po0.001. (d) K16 mRNA expression normalized to hARP in both normalized (black bars) and nonresponsive plaques (white bars). Error bars
represent the mean±SEM.
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support our concept that inflammatory DCs may be an
important pathogenic cell population in psoriasis.
Decreased DC cytokines in normalized plaques
We have previously shown that inflammatory myeloid
DCs produce tumor necrosis factor, inducible nitric oxide
synthase (iNOS), IL-20, and IL-23 (Lowes et al., 2005a;
Zaba et al., 2007a; Guttman-Yassky et al., 2008). To evaluate
the expression of these cytokines during NB-UVB treatment,
we performed quantitative real-time PCR on pre- and post-
treatment skin RNA. There were significantly increased
iNOS, IL-20, IL-12/23p40 and IL-23p19 in LS tissue
compared with NL baseline skin (Po0.05 for most compar-
isons; Figure 3a). However, significant decreases were only
observed in plaques that normalized after NB-UVB treatment
(Po0.001 for all groups). In contrast, expression of these
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Figure 2. Inflammatory myeloid dendritic cells (DCs) are reduced in normalized plaques. (a, b) Representative immunohistochemistry of CD1cþ and CD11cþ
cells. Bar¼100 mm. (c, d) Quantification of dermal CD1cþ or CD11cþ cells in normalized (black) and nonresponsive plaques (white). Each circle represents
a plaque. Non-lesional (NL) and week 6 values are compared with lesional (LS) skin values. **Po0.01, ***Po0.001. (e) CD11cþCD1c cell numbers
were calculated by subtracting CD1cþ counts from CD11cþ counts. (f) Two-color immunofluorescence of CD11c (green) and CD1c (red) of normalized
plaque. Cells coexpressing both markers appear yellow because of the superimposition of both green and red signals. Inset, high-power magnification of double-
positive cells. The white line delineates the dermoepidermal junction. Scale bar¼100 mm.
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cytokines remained high in nonresponsive plaques. Response
scores significantly correlated with IL-23p19 mRNA expres-
sion (r¼0.743, P¼ 0.008) and IL-20 (r¼0.88, P¼0.002).
We further confirmed the expression of IL-23 subunits at the
protein level by performing two-color immunofluorescence
with CD11c versus p40 or p19. Little p40 and p19 proteins
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Figure 3. Decreased dendritic cell (DC) products in normalized plaques. (a) mRNA expression levels normalized to hARP for the inflammatory DC products,
inducible nitric oxide synthase (iNOS), IL-20, IL-12/23p40, and IL-23p19, in both normalized (black bars, n¼8) and nonresponsive plaques (white bars, n¼ 6).
Error bars represent the mean±SEM. Non-lesional (NL) and week 6 levels are compared with lesional (LS) skin levels. *Po0.05, **Po0.01, ***Po0.001.
(b, c) Two-color immunofluorescence of CD11cþ myeloid DCs (red) with IL-23 subunits in a normalized plaque, (b) p40 and (c) p19 (green), showing
coexpression in baseline LS skin (yellow cells), which is diminished by week 6 after therapy. Antibodies conjugated with a fluorochrome gave background
epidermal fluorescence. The white line delineates the dermal epidermal junction. Inset, high-power magnification of double-positive cells. Scale bar¼100 mm.
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were observed in NL skin (Supplementary Figure S4 online).
LS skin showed CD11cþ cells that costained for both IL-23
subunits, and by week 6 there was a reduction in both
CD11cþ cells and the IL-23 subunits in normalized plaques
(Figure 3b and c). Some cells expressed p40 or p19, but did
not costain with CD11c, and are most likely macrophages
(Lowes, NA; unpublished data). Furthermore, in nonrespon-
sive plaques, p19 and p40 protein expression was not
reduced by NB-UVB at week 6 (Supplementary Figure S5
online). These findings indicate that after NB-UVB therapy,
normalization of psoriasis lesions is associated with a
reduction in these inflammatory mediators, further implicat-
ing their potential role in psoriasis (summarized in Supple-
mentary Figure S6 online).
Decreased T cells in normalized plaques
We have previously shown that NB-UVB therapy effectively
depletes T cells by inducing apoptosis (Ozawa et al., 1999).
We confirmed this finding showing a significant increase in
LS CD3þ T cells compared with NL skin in both dermis
(Figure 4a and b) and epidermis (Supplementary Figure S1c
online) that were reduced after NB-UVB (Po0.01). However,
we extend this observation to show that a significant
reduction in CD3þ T cells only occurs in plaques responding
to NB-UVB (Po0.001; Figure 4b). To access the biological
significance of the varying degrees of CD3þ T-cell depletion
with treatment, we correlated CD3þ T cells with response
scores. There was a strong, statistically significant correlation
between dermal CD3þ T cells and response scores
(r¼0.791, P¼0.004; Figure 4c), as well as epidermal
CD3þ T cells versus response scores (r¼0.708, P¼0.011;
Supplementary Figure S1d online). These results indicate that
a positive response to NB-UVB is associated with a profound
decrease in T cells, in addition to the myeloid inflammatory
DCs discussed above.
IL-17 and IL-22 were reduced in normalized plaques
Recent studies have implicated IL-17 and IL-22 in psoriatic
inflammation (Lowes et al., 2008; Harper et al., 2009).
We performed real-time PCR of skin tissue RNA to evaluate
pathogenic cytokine expression. We confirmed that IL-17,
IFN-g, and IL-22 were increased in LS tissue compared with
NL tissue, and there was a significant reduction in these
cytokines in normalized plaques (Po0.001 for all; Figure 5a).
In contrast, there was no reduction in these three cytokines in
nonresponsive plaques at week 6. We also found increased
LS expression of b-defensin-4 (Po0.01) and myxovirus
resistance-1 (Po0.01), the downstream target genes of
IL-17 and IFN-g, respectively, which decreased with
NB-UVB treatment only in normalized plaques (data not
shown). When cytokine mRNA was correlated with response
scores, a significant correlation was found with IL-22
(r¼0.932, P¼ 0.001) and IL-17 (r¼ 0.868; P¼0.002;
Figure 5b). On the other hand, there was no correlation
between IFN-g mRNA expression and response score
(r¼0.214, P¼ 0.445), which may indicate that expression
of IFN-g mRNA is not necessarily associated with lesion
resolution in response to NB-UVB. These cytokine data
support earlier studies showing the importance of IL-17 and
IL-22 in psoriatic inflammation, but to our knowledge, it is
previously unreported that suppressing this axis is associated
with histological normalization after NB-UVB.
It is difficult to ascertain whether cytokine-related changes
observed in the skin at the end of therapy are a direct result of
NB-UVB radiation or simply a reflection of the improvement
of psoriasis in general. Therefore, using intracellular cytokine
staining techniques, we examined the ability of a single
irradiation of 312 nm NB-UVB to modulate cytokine expres-
sion in vitro. As serial shave biopsies are difficult to obtain for
isolation of lesional T cells, we used peripheral blood
mononuclear cells as a surrogate source of T cells. Peripheral
blood mononuclear cells of normal volunteers were irra-
diated with different doses (25 or 50mJ) of NB-UVB, and
cytokine synthesis was measured after a 4-hour stimulation.
As previously observed, IFN-g was decreased by an average
of 85% (Supplementary Figure S7a online). Furthermore,
CD3þ T-cell production of IL-22 and IL-17 was significantly
decreased after NB-UVB by an average of 45 and 89%,
respectively (Supplementary Figure S7b online). These data
suggest that NB-UVB directly modulates production of these
pathogenic cytokines. Taken together, our results indicate
that NB-UVB radiation can target the IL-23/IL-17 pathway
to resolve inflammation.
DISCUSSION
In this paper, we have focused on the effects of NB-UVB at
the cellular and cytokine/inflammatory mediator levels to
define a set of outcomes that were necessary for histological
normalization after NB-UVB. Specifically, for lesion resolu-
tion there must be a reduction in myeloid inflammatory DCs
and T cells and inflammatory products (iNOS, IL-23, IL-20,
IFN-g, IL-17, and IL-22). Previous studies characterizing the
effects of NB-UVB in psoriasis have shown a downregulation
of IFN-g (Piskin et al., 2003, 2004a, b), but this study
demonstrated that there is a greater correlation between
decreased IL-22/IL-17 expression and histological improve-
ment. We have previously shown that this general set of cell
and cytokine alterations is also required for response to other
therapies for psoriasis, including alefacept, efalizumab,
etanercept, and cyclosporine (Chamian et al., 2005; Lowes
et al., 2005b; Zaba et al., 2007a; Haider et al., 2008). Despite
the fact that all of these agents work in such different ways—
targeting CD2, CD11a, tumor necrosis factor, and T cells,
respectively—their common feature is that they are all
immunosuppressive. However, it is still unclear whether
suppressing the IL-23/IL-17 axis is simply because of the
depletion of immune cells by a particular therapy, or whether
the therapy itself can specifically inhibit cytokine production.
Previous studies using flow cytometry have shown that
production of IFN-g by dermal T cells is decreased after
UVB irradiation, indicating that UVB can directly inhibit
cytokine production by T cells (Piskin et al., 2003). In this
study we also report that, in vitro, NB-UVB can directly
suppress T-cell production of IL-17 and IL-22.
Some studies have suggested that the clearing of the
inflammatory cells is specifically related to how far the
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UV radiation can penetrate (Bruls et al., 1984; Krueger et al.,
1995). For example, psoralen plus ultraviolet light A therapy,
which uses psoralen and UVA radiation, penetrates much
deeper than UVB radiation and is an even more effective
therapeutic agent for psoriasis (Yones et al., 2006; Mahmoud
et al., 2008), although it is no longer a preferred method of
treatment as it seems to increase the risk of skin cancer
(Patel et al., 2009). At the cellular level, sufficient penetration
of NB-UVB into the upper dermis results in the clearing
of myeloid DCs and T cells, which seems necessary
for reduction of inflammatory cytokine production. Further-
more, previous studies have suggested that the dermal T cells
that remain after NB-UVB produce less inflammatory
cytokines, such as IFN-g (Piskin et al., 2004a). Although we
did not directly assess IL-17 and IL-22 production by lesional
T cells, our in vitro results suggest that NB-UVB can also alter
production of proinflammatory IL-17 and IL-22.
Although some studies have shown that NB-UVB therapy
can deplete CD1aþ Langerhans cells (Murphy et al., 1993;
Tjioe et al., 2003), to our knowledge, it is previously
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Figure 4. T cells are reduced in normalized plaques. (a) Representative immunohistochemistry of CD3þ cells in non-lesional (NL), lesional (LS), and
week 6 skin of a normalized plaque. Scale bar¼ 100 mm. (b) Quantification of CD3þ T-cell counts per mm of skin in both normalized (black circles)
and nonresponsive plaques (white circles). NL and week 6 counts are compared with LS skin counts. **Po0.01, ***Po0.001. (c) Response scores were
correlated with m-scores for CD3þ cell counts. Spearman’s correlation coefficients (r) and P-values are shown.
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unreported that it can also deplete dermal inflammatory
myeloid CD11cþ DCs, both in the epidermis and the
dermis. Nonresponsive plaques retained a population of
CD11cþCD1c DCs and concurrent mRNA expression of
inflammatory DC products, indicating that depletion of these
cells is necessary for resolution of psoriatic lesions. As DCs
are the bridge between the innate and adaptive immune
systems driving subsequent T-cell responses, it seems logical
that they need to be eliminated first to prevent further T-cell
activation.
There have been some concerns stemming from data in
animal models that targeting IL-12 and IL-23 with mono-
clonal antibodies will potentially increase overall cancer risk
(Maeda et al., 2006). In humans, systemic immunosuppres-
sion clearly increases the risk of skin carcinomas and alters
their aggressiveness (Berg and Otley, 2002). Hence, it is
important to establish the potential relationship between
immunosuppression in human skin and associated cancer
risk. Suppression of p40 cytokine synthesis in the skin during
NB-UVB raises the same potential concerns as blocking p40
cytokines using monoclonal antibodies. Recent studies have
shown that careful, long-term administration of NB-UVB is
not associated with increased risk in any skin cancers,
including basal and squamous cell carcinomas and melano-
ma (Weischer et al., 2004; Hearn et al., 2008; Patel et al.,
2009). Neither is there any reported risk of internal cancer
from NB-UVB therapy. Thus, blocking the IL-23/IL-17 path-
way in the skin with NB-UVB seems to be relatively safe and
noncarcinogenic, suggesting that targeting this axis per se
does not lead to cutaneous cancer. Another factor to consider
is IL-22, as it has been shown to promote some cancers,
probably because of its trophic effects on epithelia (Bard
et al., 2008; Zhang et al., 2008). This procarcinogenic factor
is also reduced by UVB therapy.
In conclusion, this study clearly shows the set of changes
that are necessary for resolution of psoriasis lesions: a
reduction in myeloid inflammatory DCs and their products
(iNOS, IL-23, and IL-20) associated with a decrease in T cells
and additional pathogenic cytokines (IL-17, IFN-g, and
IL-22). These changes were not observed in nonresponsive
plaques. These results establish a group of cells and products
that must be effectively targeted for clearing of psoriasis, and
confirm the IL-23/IL-17 pathway as an essential therapeutic
target.
MATERIALS AND METHODS
Study design and skin biopsies
We conducted a therapeutic clinical trial under the Rockefeller
University institutional review board-approved protocol in which
14 psoriasis patients received treatment with regular, monitored
NB-UVB radiation therapy (Supplementary Table S1 online). This
trial is registered at clinicaltrials.gov under NCT00220025. Informed
consent was obtained and the study was performed in adherence
with the Declaration of Helsinki Principles. Patients were initially
treated with 50% of their minimal erythemal dose, with increments
of 5–10% 3 to 4 times per week, for up to 6 weeks. Skin punch
biopsies, 6mm in diameter, from NL skin were taken before
treatment as a baseline; pre- and post-treatment lesional biopsies
were taken from an index plaque. Each biopsy was cut in two: half
was stored in optimal cutting temperature compound for cryosec-
tions, and half snap-frozen in liquid nitrogen for RNA extractions.
Skin tissue from one plaque (normalized) was only used for RNA.
Antibodies
All antibodies used for immunohistochemistry, immunofluores-
cence, and flow cytometry are listed in Supplementary Tables
S2–S4 online.
Immunohistochemistry
Skin sections were stained as previously described (Zaba et al.,
2007b). Positive cells per mm were counted manually using
computer-assisted image analysis software (ImageJ 1.42, National
Institutes of Health, Bethesda, MD).
Immunofluorescence
Skin sections (n¼ 3 for normalized and nonresponsive plaques) were
stained as previously described (Zaba et al., 2007b). Images were
acquired using appropriate filters of a Zeiss Axioplan 2I microscope
with Plan Apochromat 20 0.7 numerical aperture lens and a
Hagamatsu orca ER-cooled charge-coupled device camera, con-
trolled by METAVUE software (MDS Analytical Technologies,
Dowingtown, PA). Dermal collagen fibers gave green autofluores-
cence. Antibodies conjugated with a fluorochrome often gave
background epidermal fluorescence. Cells coexpressing both mar-
kers appear yellow because of the superimposition of both green and
red signals. The white line delineates the dermal epidermal junction.
mRNA extraction and real-time PCR
RNA extraction and real-time PCR using Taqman gene expression
assays (Supplementary Table S5 online) were performed as
previously described (Chamian et al., 2005). Custom primers for
IFN-g, K16, and IL-12/23p40 were generated as previously described
(Chamian et al., 2005). Data normalized to hARP housekeeping
gene were quantified by software provided with Applied Biosystems
(Foster City, CA) PRISM 7700 (Sequence Detection Systems, version
1.7). The normalized PCR data were log2 transformed before
statistical analysis.
In vitro NB-UVB irradiation and flow cytometry
Peripheral blood mononuclear cells were prepared from heparinized
venous blood of healthy volunteers by Ficoll sedimentation (n¼ 3).
Cells (106 cellsml–1) were irradiated with NB-UVB (TL-01) at varying
doses (25 and 50mJ cm–2) in uncovered tissue culture plates in
phosphate-buffered saline, then stimulated for 4 hours with phorbol
myristate acetate (25 ngml–1), ionomycin (1 mgml–1), and brefeldin A
(10 mgml–1) (all from Sigma-Aldrich, St Louis, MO). Unactivated
controls were treated with brefeldin A only. Cells were stained as
previously described (Zaba et al., 2009a). Samples were acquired by
an LSR-II flow cytometer (BD Biosciences, San Jose, CA) and
analyzed using FlowJo software (Treestar, Ashland, OR).
Statistical analysis
A repeated measures analysis of variance with Tukey’s multiple
comparison test was used to compare reverse transcriptase PCR data
and cell counts from LS skin versus respective NL skin or post-
treatment skin pairs. A P-value ofo0.05 was considered significant.
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Generation of response score. The percentage change of each
gene or leukocyte count was calculated using the following formula:
((week 6LS)/(LSNL) 100). Multivariate m-scores (Wittkowski
et al., 2004) were then used to produce an overall histological
response score (‘‘response score’’) for each plaque, combining the
percentage change in epidermal thickness and K16 mRNA. We have
used this multi-variant method previously (Haider et al., 2008). The
lower the response score, the better the improvement of the index
plaque. The m-scores were also calculated for the percentage change
in expression for each gene or cell count (e.g., IL-17 score) and were
then correlated with response score by Spearman-type correlation
coefficients (r).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This research was supported by a Clinical and Translational Science Award
grant UL 1RR024143; the Doris Duke Foundation supported LMJ-H and MAL;
MAL was also supported by NIH K23 AR052404. We thank Dr A North for her
guidance with immunofluorescent images.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Aufiero BM, Talwar H, Young C et al. (2006) Narrow-band UVB
induces apoptosis in human keratinocytes. J Photochem Photobiol B
82:132–9
Baadsgaard O, Salvo B, Mannie A et al. (1990) In vivo ultraviolet-exposed
human epidermal cells activate T suppressor cell pathways that involve
CD4+CD45RA+ suppressor-inducer T cells. J Immunol 145:2854–61
Bard JD, Gelebart P, Anand M et al. (2008) Aberrant expression of IL-22
receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity
in ALK+ anaplastic large cell lymphoma. Leukemia 22:1595–603
Berg D, Otley CC (2002) Skin cancer in organ transplant recipients:
epidemiology, pathogenesis, and management. J Am Acad Dermatol
47:1–17
Blauvelt A (2008) T-helper 17 cells in psoriatic plaques and additional genetic
links between IL-23 and psoriasis. J Invest Dermatol 128:1064–7
Boniface K, Bernard FX, Garcia M et al. (2005) IL-22 inhibits epidermal
differentiation and induces proinflammatory gene expression and
migration of human keratinocytes. J Immunol 174:3695–702
Bruls WA, Slaper H, van der Leun JC et al. (1984) Transmission of human
epidermis and stratum corneum as a function of thickness in the
ultraviolet and visible wavelengths. Photochem Photobiol 40:485–94
Carrascosa JM, Tapia G, Bielsa I et al. (2007) Effects of narrowband UV-B on
pharmacodynamic markers of response to therapy: an immunohisto-
chemical study over sequential samples. J Cutan Pathol 34:769–76
Chamian F, Lowes MA, Lin SL et al. (2005) Alefacept reduces infiltrating
T cells, activated dendritic cells, and inflammatory genes in psoriasis
vulgaris. Proc Natl Acad Sci USA 102:2075–80
Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the
immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–50
Erkin G, Ugur Y, Gurer CK et al. (2007) Effect of PUVA, narrow-band
UVB and cyclosporin on inflammatory cells of the psoriatic plaque.
J Cutan Pathol 34:213–9
Goeckerman WH (1925) Treatment of psoriasis. North West Med 24:229–31
Goettsch W, Hurks HM, Garssen J et al. (1998) Comparative immunotox-
icology of ultraviolet B exposure I. Effects of in vitro and in situ
ultraviolet B exposure on the functional activity and morphology of
Langerhans cells in the skin of different species. Br J Dermatol 139:230–8
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. (2008)
Low expression of the IL-23/Th17 pathway in atopic dermatitis
compared to psoriasis. J Immunol 181:7420–7
Haider AS, Lowes MA, Suarez-Farinas M et al. (2008) Identification of cellular
pathways of ‘‘type 1,’’ Th17 T cells, and TNF- and inducible nitric oxide
synthase-producing dendritic cells in autoimmune inflammation through
pharmacogenomic study of cyclosporine A in psoriasis. J Immunol
180:1913–20
Harper EG, Guo C, Rizzo H et al. (2009) Th17 cytokines stimulate CCL20
expression in keratinocytes in vitro and in vivo: implications for psoriasis
pathogenesis. J Invest Dermatol 129:2175–83
Hearn RM, Kerr AC, Rahim KF et al. (2008) Incidence of skin cancers in
3867 patients treated with narrow-band ultraviolet B phototherapy.
Br J Dermatol 159:931–5
Krueger JG, Wolfe JT, Nabeya RT et al. (1995) Successful ultraviolet B
treatment of psoriasis is accompanied by a reversal of keratinocyte
pathology and by selective depletion of intraepidermal T cells. J Exp Med
182:2057–68
Lebwohl M (2003) Psoriasis. Lancet 361:1197–204
Lowes M, Chamian F, Abello MV et al. (2005a) Increase in TNF-alpha and
inducible nitric oxide synthase-expressing dendritic cells in psoriasis and
reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA
102:19057–62
Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008) Psoriasis vulgaris
lesions contain discrete populations of Th1 and Th17 T cells. J Invest
Dermatol 128:1207–11
Lowes MA, Turton JA, Krueger JG et al. (2005b) Psoriasis vulgaris flare
during efalizumab therapy does not preclude future use: a case series.
BMC Dermatol 5:9
Maeda A, Schneider SW, Kojima M et al. (2006) Enhanced photocarcinogen-
esis in interleukin-12-deficient mice. Cancer Res 66:2962–9
Mahmoud BH, Hexsel CL, Hamzavi IH et al. (2008) Effects of visible light on
the skin. Photochem Photobiol 84:450–62
Murphy GM, Norris PG, Young AR et al. (1993) Low-dose ultraviolet-B
irradiation depletes human epidermal Langerhans cells. Br J Dermatol
129:674–7
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509
Nograles KE, Zaba LC, Guttman-Yassky E et al. (2008) Th17 cytokines
interleukin (IL)-17 and IL-22 modulate distinct inflammatory and
keratinocyte-response pathways. Br J Dermatol 159:1086–91
Noonan FP, De Fabo EC, Morrison H (1988) Cis-urocanic acid, a product
formed by ultraviolet B irradiation of the skin, initiates an antigen
presentation defect in splenic dendritic cells in vivo. J Invest Dermatol
90:92–9
Ozawa M, Ferenczi K, Kikuchi T et al. (1999) 312-nanometer ultraviolet
B light (narrow-band UVB) induces apoptosis of T cells within psoriatic
lesions. J Exp Med 189:711–8
Patel RV, Clark LN, Lebwohl M et al. (2009) Treatments for psoriasis and the
risk of malignancy. J Am Acad Dermatol 60:1001–17
Pene J, Chevalier S, Preisser L et al. (2008) Chronically inflamed
human tissues are infiltrated by highly differentiated Th17 lymphocytes.
J Immunol 180:7423–30
Piskin G, Koomen CW, Picavet D et al. (2003) Ultraviolet-B irradiation
decreases IFN-gamma and increases IL-4 expression in psoriatic lesional
skin in situ and in cultured dermal T cells derived from these lesions.
Exp Dermatol 12:172–80
Piskin G, Sylva-Steenland RM, Bos JD et al. (2004a) T cells in psoriatic
lesional skin that survive conventional therapy with NB-UVB
radiation display reduced IFN-gamma expression. Arch Dermatol Res
295:509–16
Piskin G, Tursen U, Sylva-Steenland RM et al. (2004b) Clinical improvement
in chronic plaque-type psoriasis lesions after narrow-band UVB therapy
is accompanied by a decrease in the expression of IFN-gamma
inducers—IL-12, IL-18 and IL-23. Exp Dermatol 13:764–72
Sa SM, Valdez PA, Wu J et al. (2007) The effects of IL-20 subfamily cytokines
on reconstituted human epidermis suggest potential roles in cutaneous
2662 Journal of Investigative Dermatology (2010), Volume 130
LM Johnson-Huang et al.
Narrow-Band UVB Suppresses IL-23/IL-17 Axis
innate defense and pathogenic adaptive immunity in psoriasis.
J Immunol 178:2229–40
Sigmundsdottir H, Johnston A, Gudjonsson JE et al. (2005) Narrowband-UVB
irradiation decreases the production of pro-inflammatory cytokines by
stimulated T cells. Arch Dermatol Res 297:39–42
Simon JC, Tigelaar RE, Bergstresser PR et al. (1991) Ultraviolet B radiation
converts Langerhans cells from immunogenic to tolerogenic antigen-
presenting cells. Induction of specific clonal anergy in CD4+ T helper 1
cells. J Immunol 146:485–91
Tjioe M, Smits T, van de Kerkhof PC et al. (2003) The differential effect of
broad band vs narrow band UVB with respect to photodamage and
cutaneous inflammation. Exp Dermatol 12:729–33
Walters IB, Burack LH, Coven TR et al. (1999) Suberythemogenic narrow-
band UVB is markedly more effective than conventional UVB in
treatment of psoriasis vulgaris. J Am Acad Dermatol 40:893–900
Walters IB, Ozawa M, Cardinale I et al. (2003) Narrowband (312-nm) UV-B
suppresses interferon gamma and interleukin (IL) 12 and increases IL-4
transcripts: differential regulation of cytokines at the single-cell level.
Arch Dermatol 139:155–61
Weischer M, Blum A, Eberhard F et al. (2004) No evidence for increased skin
cancer risk in psoriasis patients treated with broadband or narrowband
UVB phototherapy: a first retrospective study. Acta Derm Venereol
84:370–4
Wittkowski KM, Lee E, Nussbaum R et al. (2004) Combining several ordinal
measures in clinical studies. Stat Med 23:1579–92
Yones SS, Palmer RA, Garibaldinos TT et al. (2006) Randomized double-blind
trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-
UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 142:836–42
Zaba L, Cardinale I, Gilleaudeau P et al. (2007a) Amelioration of epidermal
hyperplasia by TNF inhibition is associated with reduced Th17
responses. J Exp Med 204:3183–94
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2009a) Psoriasis is
characterized by accumulation of immunostimulatory and Th1/Th17
cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:79–88
Zaba LC, Fuentes-Duculan J, Steinman RM et al. (2007b) Normal human
dermis contains distinct populations of CD11cBDCA-1 dendritic cells
and CD163FXIIIA macrophages. J Clin Invest 117:2517–25
Zaba LC, Krueger JG, Lowes MA (2009b) Resident and ‘‘inflammatory’’
dendritic cells in human skin. J Invest Dermatol 129:302–8
Zhang W, Chen Y, Wei H et al. (2008) Antiapoptotic activity of autocrine
interleukin-22 and therapeutic effects of interleukin-22-small interfering
RNA on human lung cancer xenografts. Clin Cancer Res 14:6432–9
www.jidonline.org 2663
LM Johnson-Huang et al.
Narrow-Band UVB Suppresses IL-23/IL-17 Axis
